Updated Jaundice Guidelines Cut Interventions, Lower Costs

New evidence from a hospital in Italy suggests a major shift in newborn jaundice care could safely reduce medical interventions, lower costs, and keep more families together postpartum. The research tests updated American guidelines that are less aggressive in treating common, non-dangerous jaundice.

A Simulated Trial Shows a Clear Path to Less Intervention

Researchers at the Spedali Civili Children’s Hospital in Brescia, led by neonatologist Francesco Maria Risso, wanted to understand what would happen if they changed how they manage newborn jaundice, or hyperbilirubinemia. Jaundice, caused by a buildup of a yellow pigment called bilirubin, is extremely common. While severe cases can cause permanent brain damage, most are harmless and resolve on their own.

The team retrospectively applied the AAP’s 2022 guidelines to 904 newborns who had been treated under Italy’s more conservative national recommendations between November 2024 and February 2025. They simulated which babies would have been treated under the new rules. The difference was stark: phototherapy use would have dropped by 69.8%. For the 904 infants, this meant 98 fewer days spent under lights in the hospital. The trade-off was a 37.9% increase in post-discharge blood checks to monitor bilirubin levels as outpatients.

Why Higher Treatment Thresholds Are Now Considered Safe

The mechanism behind this change is a recalibration of risk. Bilirubin is a normal byproduct of red blood cell breakdown. A newborn’s liver, which processes and excretes bilirubin, is often immature. High levels can cross the blood-brain barrier and cause kernicterus, a form of permanent neurological damage.

For decades, guidelines were designed to be highly precautionary to prevent this rare outcome. However, accumulating evidence indicates the danger threshold for healthy infants born at 35 weeks gestation or later is higher than previously thought. The 2022 AAP guidelines reflect this by setting higher bilirubin levels to trigger phototherapy, but only for babies without specific risk factors like certain blood incompatibilities, significant bruising, or poor feeding. The Italian study found only 5.3% of their cohort had these risk factors, meaning the vast majority were candidates for the more permissive approach.

Phototherapy itself, while effective, is not without consequence. It separates the newborn from parents, can disrupt feeding, and requires eye protection. Reducing its use when medically safe supports parental confidence and bonding in the critical early days.

Economic and Organizational Impacts Beyond the Bassinet

The financial and logistical results from the simulation were clear. The hospital’s management team calculated a reduction of €16,591.58 in variable costs over just four months, primarily from saved phototherapy equipment use, nursing time, and bed occupancy. Freeing up nearly 100 bed-days improves hospital flow, potentially allowing other infants needing intensive care to be admitted.

This represents a significant shift in resource allocation—from inpatient treatment to outpatient surveillance. The study authors note this enhances “neonatal care efficiency,” but it also transfers a portion of the monitoring burden to community care. Successfully implementing such a change requires robust systems for follow-up and clear communication with parents to ensure discharged babies receive their necessary bilirubin checks, a point the researchers acknowledge requires longitudinal study.

Practical Guidance for Parents in a Transition Period

For expectant and new parents, this research highlights the evolving nature of evidence-based medicine. Practices change as science provides clearer answers. If your hospital adopts guidelines similar to the AAP’s 2022 standards, you might see:

• Less routine phototherapy: Your healthy, feeding well, term baby may not be treated for jaundice levels that would have triggered treatment a few years ago.
• More emphasis on feeding: Effective breastfeeding or formula feeding helps flush bilirubin from the body. Supporting successful feeding is a primary preventive strategy.
• Strict attention to follow-up: You may be asked to return to the clinic or pediatrician’s office for one or more bilirubin blood tests after discharge. This outpatient monitoring is the essential counterpart to reduced hospital treatment.
• Vigilance for risk factors: Medical staff will carefully assess your baby for conditions like blood type incompatibility with the mother, which would make them ineligible for the higher thresholds and require more traditional, cautious management.

The goal is not simply to cut costs, but to apply care more precisely—treating the infants who truly need intervention while avoiding unnecessary separation and treatment for the majority. As the Italian team concludes, this simulation encouraged them to adopt the new guidelines, but they will continue to monitor the safety and real-world effects of the change.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42213232/
https://pubmed.ncbi.nlm.nih.gov/42212814/
https://pubmed.ncbi.nlm.nih.gov/42200327/